OBJECTIVES: To evaluate the effects of Trigonella foenum-graecum (fenugreek) seeds on glycemic control and insulin resistance, determined by HOMA model, in mild to moderate type 2 diabetes mellitus we performed a double blind placebo controlled study. METHODS:Twenty five newly diagnosed patients with type 2 diabetes (fasting glucose < 200 mg/dl) were randomly divided into two groups. Group I (n=12) received 1 gm/day hydroalcoholic extract of fenugreek seeds and Group II (n=13) received usual care (dietary control, exercise) and placebo capsules for two months. RESULTS: At baseline both the groups were similar in anthropometric and clinical variables. Oral glucose tolerance test, lipid levels, fasting C-peptide, glycosylated haemoglobin, and HOMA-model insulin resistance were also similar at baseline. In group 1 as compared to group 2 at the end of two months, fasting blood glucose (148.3 +/- 44.1 to 119.9 +/- 25 vs. 137.5 +/- 41.1 to 113.0 +/- 36.0) and two hour postglucose blood glucose (210.6 +/- 79.0 to 181.1 +/- 69 vs. 219.9 +/- 41.0 to 241.6 +/- 43) were not different. But area under curve (AUC) of blood glucose (2375 +/- 574 vs 27597 +/- 274) as well as insulin (2492 +/- 2536 vs. 5631 +/- 2428) was significantly lower (p < 0.001). HOMA model derived insulin resistance showed a decrease in percent beta-cell secretion in group 1 as compared to group 2 (86.3 +/- 32 vs. 70.1 +/- 52) and increase in percent insulin sensitivity (112.9 +/- 67 vs 92.2 +/- 57) (p < 0.05). Serum triglycerides decreased and HDL cholesterol increased significantly in group 1 as compared to group 2 (p < 0.05). CONCLUSIONS: Adjunct use of fenugreek seeds improves glycemic control and decreases insulin resistance in mild type-2 diabetic patients. There is also a favourable effect on hypertriglyceridemia.
RCT Entities:
OBJECTIVES: To evaluate the effects of Trigonella foenum-graecum (fenugreek) seeds on glycemic control and insulin resistance, determined by HOMA model, in mild to moderate type 2 diabetes mellitus we performed a double blind placebo controlled study. METHODS: Twenty five newly diagnosed patients with type 2 diabetes (fasting glucose < 200 mg/dl) were randomly divided into two groups. Group I (n=12) received 1 gm/day hydroalcoholic extract of fenugreek seeds and Group II (n=13) received usual care (dietary control, exercise) and placebo capsules for two months. RESULTS: At baseline both the groups were similar in anthropometric and clinical variables. Oral glucose tolerance test, lipid levels, fasting C-peptide, glycosylated haemoglobin, and HOMA-model insulin resistance were also similar at baseline. In group 1 as compared to group 2 at the end of two months, fasting blood glucose (148.3 +/- 44.1 to 119.9 +/- 25 vs. 137.5 +/- 41.1 to 113.0 +/- 36.0) and two hour postglucose blood glucose (210.6 +/- 79.0 to 181.1 +/- 69 vs. 219.9 +/- 41.0 to 241.6 +/- 43) were not different. But area under curve (AUC) of blood glucose (2375 +/- 574 vs 27597 +/- 274) as well as insulin (2492 +/- 2536 vs. 5631 +/- 2428) was significantly lower (p < 0.001). HOMA model derived insulin resistance showed a decrease in percent beta-cell secretion in group 1 as compared to group 2 (86.3 +/- 32 vs. 70.1 +/- 52) and increase in percent insulin sensitivity (112.9 +/- 67 vs 92.2 +/- 57) (p < 0.05). Serum triglycerides decreased and HDL cholesterol increased significantly in group 1 as compared to group 2 (p < 0.05). CONCLUSIONS: Adjunct use of fenugreek seeds improves glycemic control and decreases insulin resistance in mild type-2 diabeticpatients. There is also a favourable effect on hypertriglyceridemia.